Heron Therapeutics (HRTX) Price to Sales (2017 - 2026)

Heron Therapeutics (HRTX) has reported Price to Sales for 10 consecutive years, with 2.17 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales fell 74.59% year-over-year to 2.17; the trailing twelve-month figure through Jun 2026 stood at 0.54 (down 74.53% YoY), and the FY2025 full-year result was 1.58, down 2.03% from the prior year.
• Price to Sales eased to 2.17 in Q2 2026 per HRTX's latest filing, from 4.36 in the prior quarter.
• Across five years, Price to Sales topped out at 24.99 in Q1 2022 and bottomed at 2.17 in Q2 2026.
• Historically, Price to Sales has averaged 9.18 across 5 years, with a median of 8.0 in 2025.
• The sharpest annual moves came in 2022 and 2024: Price to Sales sank 85.29% in 2022, then jumped 186.64% in 2024.
• Over 5 years, Price to Sales stood at 9.92 in 2022, then fell by 24.77% to 7.46 in 2023, then fell by 23.52% to 5.71 in 2024, then advanced by 5.68% to 6.03 in 2025, then plunged by 64.07% to 2.17 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 2.17, 4.36, and 6.03 for Q2 2026, Q1 2026, and Q4 2025 respectively.